Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H24ClFO7.C5H9NO2 |
Molecular Weight | 570.004 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)[C@H]1CCCN1.CCOC2=CC=C(CC3=CC(=CC=C3Cl)[C@@]45OC[C@@](CO)(O4)[C@@H](O)[C@H](O)[C@H]5O)C=C2F
InChI
InChIKey=HSHUXRQZEKRWMX-CGDHVTPMSA-N
InChI=1S/C22H24ClFO7.C5H9NO2/c1-2-29-17-6-3-12(8-16(17)24)7-13-9-14(4-5-15(13)23)22-20(28)18(26)19(27)21(10-25,31-22)11-30-22;7-5(8)4-2-1-3-6-4/h3-6,8-9,18-20,25-28H,2,7,10-11H2,1H3;4,6H,1-3H2,(H,7,8)/t18-,19-,20+,21+,22+;4-/m01/s1
Molecular Formula | C22H24ClFO7 |
Molecular Weight | 454.873 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | C5H9NO2 |
Molecular Weight | 115.1305 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Henagliflozin (also known as SHR3824) was developed by Jiangsu HengRui Medicine as a sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. This drug successfully passed phase I clinical trials, however, information about further development is not available.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
SHR3824, a novel selective inhibitor of renal sodium glucose cotransporter 2, exhibits antidiabetic efficacy in rodent models. | 2014 May |
|
Evaluation of drug-drug interaction between henagliflozin, a novel sodium-glucose co-transporter 2 inhibitor, and metformin in healthy Chinese males. | 2016 Aug |
|
Pharmacokinetics and Pharmacodynamics of Henagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Chinese Patients with Type 2 Diabetes Mellitus. | 2016 Mar |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02346175
to evaluate the pharmacodynamics (PD), pharmacokinetics (PK), safety and tolerability following single and multiple oral doses of 5mg to 20 mg SHR3824 in Type 2 diabetes mellitus patients.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 15:33:40 GMT 2023
by
admin
on
Sat Dec 16 15:33:40 GMT 2023
|
Record UNII |
4IO819SW6M
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
146019519
Created by
admin on Sat Dec 16 15:33:40 GMT 2023 , Edited by admin on Sat Dec 16 15:33:40 GMT 2023
|
PRIMARY | |||
|
4IO819SW6M
Created by
admin on Sat Dec 16 15:33:40 GMT 2023 , Edited by admin on Sat Dec 16 15:33:40 GMT 2023
|
PRIMARY | |||
|
300000040273
Created by
admin on Sat Dec 16 15:33:40 GMT 2023 , Edited by admin on Sat Dec 16 15:33:40 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |